The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2013
Filed:
Jan. 31, 2011
Steven DO, South San Francisco, CA (US);
Richard Goldsmith, South San Francisco, CA (US);
Tim Heffron, South San Francisco, CA (US);
Aleksandr Kolesnikov, South San Francisco, CA (US);
Steven Staben, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Michael Siu, South San Francisco, CA (US);
Daniel P. Sutherlin, South San Francisco, CA (US);
Bing-yan Zhu, South San Francisco, CA (US);
Paul Goldsmith, Basel, CH;
Tracy Bayliss, Basel, CH;
Adrian Folkes, Basel, CH;
Neil Pegg, Basel, CH;
Steven Do, South San Francisco, CA (US);
Richard Goldsmith, South San Francisco, CA (US);
Tim Heffron, South San Francisco, CA (US);
Aleksandr Kolesnikov, South San Francisco, CA (US);
Steven Staben, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Michael Siu, South San Francisco, CA (US);
Daniel P. Sutherlin, South San Francisco, CA (US);
Bing-Yan Zhu, South San Francisco, CA (US);
Paul Goldsmith, Basel, CH;
Tracy Bayliss, Basel, CH;
Adrian Folkes, Basel, CH;
Neil Pegg, Basel, CH;
Genentech, Inc., South San Francisco, CA (US);
F. Hoffman-La Roche Inc., Nutley, NJ (US);
Abstract
Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.